Newron Pharmaceuticals SpA

NWRN Eur0.20
Create an alert
Sell10.70 CHF
Buy12.40 CHF
0.28 CHF (2.58%)
Last updated today at

To trade with this investment contact our helpdesk

Online trading unavailable
Back to dashboard

Company Information

About this company

Newron Pharmaceuticals SpA is an Italy-based company operating in the medical research sector. It is a biopharmaceutical company focused on the research, development, and commercialization of therapies for disorders of the central and peripheral nervous system (CNS). The Company specializes in neurological and psychiatric diseases, including schizophrenia and Parkinson’s disease. Its activities include drug discovery, clinical development, regulatory approval processes, and strategic licensing and commercialization partnerships with pharmaceutical companies worldwide. The Company has built a pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization, such as evenamide, safinamide and ralfinamide. Newron Pharmaceuticals SpA operates at global level.

Key people

Chris Martin
Non-Executive Chairman of the Board
Stefan Weber
Chief Executive Officer, Executive Director
Roberto Galli
Chief Financial Officer
Filippo Moriggia
Vice President - Operations
Dennis Dionne
Vice President - Commercial Affairs
Laura Faravelli
Vice President - Business Development
Ravi Anand
Chief Medical Officer
Margarita Chavez
Non-Executive Independent Director
Gillian Dines
Non-Executive Independent Director
Click to see more

Key facts

  • Shares in issue
    21.24m
  • EPIC
    NWRN
  • ISIN
    IT0004147952
  • Location
    Italy
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    CHF 230.58m
  • Employees
    27
  • Exchange
    SIX Swiss Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.